Growth consulting. Regulatory strategy.
No press logos are claimed. The operating record stands on primary public sources.
The advice comes from someone who has been accountable for the outcome, not only for the memo.
Each engagement starts with the constraint that is actually holding the business back, then works the problem in the order that money and regulators respond to.
Revenue, margin, and operating discipline for clinics, practices, diagnostics groups, and investor-backed healthcare services. Fix what is leaking before adding what is new.
Business growth consulting for healthcare and biotechPathway mapping, milestone planning, and pressure-testing the clinical, operational, and compliance plan before it meets a regulator. Strategy support, not legal advice.
Regulatory strategy advisory for FDA-regulated venturesNew clients start with a short, paid Diagnostic Advisory Engagement. In that engagement I assess your growth performance and your regulatory position together, because in an FDA-regulated business they are one system. What the regulator lets you do decides what you can sell and when you can sell it. A growth plan built without that constraint is a forecast, not a plan.
We set the objective, the constraints, and what a useful answer looks like for you.
I go through what the business actually shows rather than what the deck says.
We test the findings against your reality and pressure the options together.
The written strategy report lands, and we walk it end to end.
The engagement ends with a written strategy report and a live strategy session. The report gives you a clear picture of your growth performance and your regulatory position, and of how each one is constraining the other. The session turns that picture into concrete decisions and next steps. The report is something you can take to your board, your investors, and your counsel.
After the diagnostic, we either move into focused work on growth or on regulatory strategy, or you take the findings and act on them with your own team. The diagnostic stands on its own. It is not a sales call with a fee attached.
Discipline with capital is treated as a competitive advantage, not a constraint.Operating principle
Recommendations follow a fixed order. Documented facts outrank narrative, and where the evidence is thin, the recommendation says so.
The regulatory pathway is settled before anything else. It sets the requirements every later decision answers to.
Scientific and regulatory claims are weighed against primary sources, filings, and the published literature.
The capital plan is built to the pathway, with burn discipline and an operating cadence that matches the stage.
The team and execution risk are tested against the plan. Assumptions are stated so a reader can check them.
The operating history behind this advisory is documented in primary public sources, including SEC EDGAR filings and the CMS provider registry.
A brief qualifying exchange comes first, so we both know the diagnostic is the right use of your money. The fee is set out in the proposal, not on this page.